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Abstract
Background:  Androgens  have  been  used  to  treat  bone  marrow  failure  syndromes  such  as  aplastic
anaemia  (AA)  since  the  1970s,  and  are  currently  used  as  adjuvants  to  other  treatment  regimens.
Objective:  To  determine  the  efﬁcacy  and  response  time  of  androgens  in  the  treatment  of  AA.
Materials and  methods:  A  retrospective,  analytical-observational  nested  study  in  a  cohort  of
patients with  AA.  The  study  was  conducted  from  January  2006  to  December  2013.
Results:  A  total  of  63  patients  with  a  mean  age  of  47  (18--83)  years  were  included  in  the  study.
Out of  27  patients  in  full  remission,  17  received  some  type  of  immunosuppressant  combined  with
androgens.  The  use  of  more  than  2  immunosuppressants  did  not  signiﬁcantly  improve  response
times (p  =  0.311,  95%  CI).  Mean  response  time  was  725  (331--1119)  days;  4-year  survival  rate
was 86%.
Conclusions:  Improved  immunosuppressant  response  rates  with  adjuvant  androgens  were
mainly observed  in  patients  with  severe  AA.
© 2015  Published  by  Masson  Doyma  México  S.A.  on  behalf  of  Sociedad  Médica  del  Hospital
General  de  México.
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Antecedentes:  Desde  los  sesenta  se  utilizan  andrógenos  para  tratar  síndromes  de  falla  medular,
como la  anemia  aplásica  (AA),  actualmente  son  complemento  a  otros  tratamientos.
Objetivo:  Establecer  la  eﬁcacia  y  tiempo  de  respuesta  al  tratamiento  con  andrógenos  en  AA.
Material  y  Métodos:  Estudio  retrospectivo,  observacional-analítico  anidado  en  la  cohorte  de
pacientes portadores  de  AA  durante  enero  2006  a  diciembre  2013.
∗ Corresponding author at: Dr. Balmis 148, Col. Doctores, C.P. 06726 Mexico City, Mexico.
E-mail address: leukemiachop@hotmail.com (C.O. Ramos-Pen˜aﬁel).
http://dx.doi.org/10.1016/j.hgmx.2015.07.002
0185-1063/© 2015 Published by Masson Doyma México S.A. on behalf of Sociedad Médica del Hospital General de México.
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Resultados:  Se  estudiaron  63  pacientes,  con  edad  media  de  47  (18--83)  an˜os.  De  27  pacientes
(42.9%) que  integraron  remisión  completa,  17  recibían  algún  inmunosupresor  en  conjunto  con
andrógenos.  Usar  más  de  2  inmunosupresores  elevó  no  signiﬁcativamente  (p  =  0.311,  95%IC)  las
respuestas.  La  media  de  respuesta  fue  de  725  (331--1,119)  días.  La  supervivencia  a  4  an˜os  fue
del 86%.
Conclusiones:  Adicionar  andrógenos  mejoró  la  tasa  de  respuesta  a  los  inmunosupresores  prin-
cipalmente  en  pacientes  con  AA  muy  severa.
© 2015  Publicado  por  Masson  Doyma  México  S.A.  en  nombre  de  Sociedad  Médica  del  Hospital
General de  México.
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plastic  anaemia  (AA)  is  an  immune  disease  character-
zed  by  varying  degrees  of  peripheral  cytopaenia  and
atty  replacement  of  haematopoietic  tissue.1 Response  to
mmunosuppressants  varies,  but  cyclosporine  plus  anti-
hymocyte  globulin  (ATG)  generally  achieves  a  response  rate
f  over  60%.2,3 The  combination  of  haematopoietic  stem  cell
ransplant  and  immunosuppressant  therapy  has  increased
he  survival  rate  of  AA  patient  to  over  80%  worldwide,  with
 second  cycle  of  ATGs  or  administration  of  new  throm-
omimetic  drugs  being  reserved  for  refractory  cases.4,5 Prior
o  these  therapeutic  advances,  evidence  from  a  number  of
ase  series  led  to  androgens  being  included  in  regimens
o  treat  bone  marrow  failure  syndromes.6,7 In  the  1970s,
ttempts  were  made  to  combine  them  with  other  options
uch  as  steroids,8,9 but  it  was  not  until  the  end  of  that
ecade  that  they  were  ﬁrst  combined  with  haematopoietic
tem  cell  transplant.9,10 In  the  mid  1980s,  Champlin  et  al.
ublished  the  ﬁrst  prospective  study  in  121  patients  receiv-
ng  androgens  as  adjuvant  to  ATGs.  The  study  found  no
igniﬁcant  differences  in  remission  rates.11 Following  this,
nterest  in  androgens  faded,  and  their  use  was  limited  to
 few  small  series.  In  Mexico,  Pérez  et  al.  evaluated  the
fﬁcacy  of  danazol  as  ﬁrst  line  therapy,  and  reported  a
ean  response  time  of  3  months,  with  an  overall  response
ate  of  46%.12 In  the  General  Hospital  of  Mexico,  standard
reatment  is  based  on  immunosuppressants  in  combination
ith  different  types  of  androgens.  The  main  aim  of  this
tudy  has  been  to  evaluate  combination  therapy  with  andro-
ens  and  immunosuppressants  in  terms  of  response  time  and
ate.
ethods
tudy  design
e  carried  out  a  retrospective  chart  review  of  patients  with
cquired  AA  seen  in  the  General  Hospital  of  Mexico  from
anuary  2006  to  December  2013.
All  patients  meeting  diagnostic  criteria  for  AA  whose
rimary  treatment  had  included  androgens  alone  or  in  com-
ination  with  immunosuppressants.  Diagnosis  of  AA  was
eﬁned  by  at  least  2  of  the  following  criteria:  haemoglobin
ess  than  10  g/dL,  platelet  count  less  than  50  ×  109/L,  neu-
rophil  count  less  than  1.5  ×  109/L  and  hypercellular  bone
arrow.
S
(
KExclusion  criteria  were:  incomplete  medical  record,
herapy  including  bone  marrow  stimulants,  evidence  of
aroxysmal  nocturnal  haemoglobinuria  (PNH)  with  haemol-
sis,  history  of  thrombosis  associated  with  PNH  or  clone
reater  that  50%  on  ﬂow  cytometry,  pregnancy,  or  prior  diag-
osis  of  malignancy.
The  clinical  and  laboratory  reports  of  study  patients
t  the  time  of  diagnosis,  together  with  the  therapy  used,
he  clinical  course,  transfusion  requirements,  and  date  of
he  last  visit  were  recorded.  Cases  were  categorized  as
oderate  and  severe  AA  according  to  severity,  which  was
ssessed  on  the  basis  of  neutrophil  and  platelet  count  at
he  time  of  diagnosis.  The  severe  group  was  later  divided
nto  severe  and  very  severe.13
reatment  protocol
he  immunosuppressant  cyclosporin  A  (CpA)  was  adminis-
ered  daily  (5  mg/kg)  to  maintain  levels  of  150--250  ng/mL.
ther  immunosuppressants  used  in  combination  with  CpA
ere  mycophenolate  mofetil  and  prednisone  (1  mg/kg).  Red
lood  cell  (RBC)  or  platelet  transfusion  was  ordered  at  the
iscretion  of  the  attending  physician.  Response  to  treatment
as  evaluated  on  the  basis  of  established  criteria.13
ndrogens
he  androgens  most  commonly  used  were  danazol  and
esterolone,  followed  by  testosterone  and  oxymetholone.
anazol  was  given  orally  at  200  mg  every  8  h,  and  was  either
tepped  down  or  suspended  at  the  discretion  of  the  attend-
ng  physician.
thical  considerations
eing  a retrospective  study,  the  data  were  sourced  from
edical  records  held  in  the  Haematology  Departments.
ccess  to  these  was  strictly  controlled,  in  accordance  with
egulations  in  force  in  Mexico,  and  patient  privacy  and
nonymity  was  maintained  at  all  times.
tatistical  analysistudy  data  were  analyzed  using  IBM  SPSS  version  20.0
Armonk,  New  York).  Overall  survival  was  estimated  using
aplan--Meier  curves;  response  of  each  severity  category
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Table  1  General  characteristics  of  patients.
Characteristics  Mean  Range
Laboratory  tests
Leukocytes  (×103/mcl)  2.3  0.5--4.6
Neutrophils  (×103/mcl)  0.6  0.04--1.3
Lymphocytes  (×103/mcl)  1.52  0.1--3.37
Haemoglobin  (g/dL)  7.36  2.8--8.3
Platelets  (×103/mcl)  20.35  1.0--8.4
Characteristics  (n=)  (%)
Risk  group
Moderate  AA  23  36.5
Severe AA  16  25.4
Very severe  AA  24  38.1
Karyotype
Not available  24  38.1
Normal karyotype  36  57.2
46 XX  del  7q  1  1.6
46XX polyploid  1  1.6
Trisomy  19,16  and  18  1  1.6
PNH clone  <  50%  4  6.3
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Patients  in  the  moderate  group  received  a mean  of  11.04
RCB  transfusions  vs.  11.89  in  the  severe  group.  The  most
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(severe disease)Abbreviations:  AA: aplastic anaemia; PNH: paroxysmal nocturnal
haemoglobinuria.
was  estimated  using  the  log  rank  test.  Inter-group  compar-
isons  were  estimated  using  the  chi-squared  test;  signiﬁcance
was  set  at  p  ≤  0.05  (5%).
Results
Of  the  63  patients  included  in  the  study,  3  were  excluded
due  to  a  large  PNH  clone  size.  The  mean  age  was  47.7  years
(range  18--83  years);  52.4%  of  patients  were  men  (n  =  33)  and
47.6%  were  women  (n  =  30).  Table  1  shows  the  characteristics
of  the  patients  at  the  time  of  diagnosis.
Treatment  with  immunosuppressants  and
androgens
The  most  commonly  used  immunosuppressant  was  CpA
(87%),  both  alone  or  in  combination  with  other  immuno-
suppressants.  Prednisone  was  given  at  some  time  to  13%  of
patients,  and  17%  received  mycophenolate  mofetil.  Only  3%
received  rabbit  anti-thymocyte  globulin.  As  the  regimen  has
not  been  standardized,  patients  were  given  various  types
of  androgens,  with  danazol  being  the  most  commonly  used
(95%).  Nearly  75%  of  patients  given  oxymetholone  as  pri-
mary  therapy  had  switched  to  danazol  by  the  end  of  their
treatment.  In  terms  of  primary  therapy,  73%  (n  =  46)  were
given  danazol,  20.6%  (n  =  20.6)  mesterolone,  4.8%  (n  =  3)
oxymetholone,  and  1.6%  (n  =  1)  testosterone.
Follow-up  and  responseMean  follow-up  was  683  days  (150--1507  days).  Mean
response  time  was  745  days  in  the  severe  group  (severe/very
severe)  and  341  days  in  the  moderate  group.  In  the  severe
group,  45%  (n  =  18)  of  patients  classiﬁed  as  severe  (asFollow-up (days)
Figure  1  Overall  survival  curve  at  4  years  of  follow-up.
pposed  to  very  severe),  responded  to  treatment,  vs.  39.1%
n  the  moderate  group.  Although  response  varied  between
roups,  the  differences  were  not  statistically  signiﬁcant
p  =  0.427,  95%  CI).  In  total,  50.8%  of  patients  took  a  combi-
ation  of  2  or  more  immunosuppressants,  mainly  mycophe-
olate  and  cyclosporine,  while  49.2%  received  monotherapy,
ainly  prednisone  or  cyclosporine  A.  No  signiﬁcant  dif-
erences  in  type  of  response  were  observed  between
onotherapy  and  combination  therapy  (p  =  0.182,  95%  CI).
urvival
verall  survival  rates  exceeded  86%  at  4  years  of  follow  up,
ith  no  signiﬁcant  differences  between  groups  in  terms  of
everity  of  disease  (p  =  0.315).  Survival  curves  are  shown  in
igs.  1  and  2.
ransfusions0 500
Follow-up (days)
1000 1500 2000 (n)
Figure  2  Survival  curve  by  severity  at  4  years  of  follow-up.
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Table  2  Transfusion  requirements  during  treatment  for  aplastic  anaemia.
Moderate  AA  Severe  AA
Number  of  bags  11.04  (7.8--30)  11.89  (9.1--73)
Interquartile range  5  9.75
Variance 53.04  73.49
Moderate  AA  Severe  AA  Very  severe  AA
Number  of  bags 11.04  (7.8--30)  14.37  (9.7--34)  10.28  (9.1--73)
Interquartile range 5  10.5  11.75
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isperse  data  were  found  in  the  severe  group  (variance:
3.04  vs.  73.49;  interquartile  range:  5  vs.  9.75),  and  for
his  reason  the  group  was  divided  into  severe  and  very
evere  cases.  Having  divided  the  group,  we  were  able  to
bserve  that  although  severe  AA  patients  required  more
ransfusions,  even  exceeding  very  severe  patients  (14.37  vs.
0.28),  most  of  these  were  probably  due  to  atypical  cases
interquartile  range:  10.5  vs.  11.75)  (see  Table  2).
iscussion
he  mechanism  of  action  of  androgens  in  bone  marrow
ailure  syndromes  remained  obscure  for  over  30  years.
he  studies  published  by  Sánchez-Medal  in  the  mid-1970s
escribed  how  different  types  of  androgens  could  improve
ytopaenia  in  aplastic  anaemia,  mainly  in  patients  with
oderate  disease.14,15 Interest  in  the  therapy  gradually
aded,  until  it  was  eventually  ignored  in  most  therapeu-
ic  guidelines.13,16 Although  evidence  in  the  literature  has
onsistently  shown  the  scant  beneﬁcial  therapeutic  effect
f  androgens,  most  physicians  continue  to  use  it  regu-
arly,  either  in  monotherapy  or  in  combination  with  an
mmunosuppressant.  Our  hospital  has  gradually  introduced
 range  of  therapeutic  strategies  for  management  of
plastic  anaemia  (prednisone,  cyclosporine,  anti-CD52,
nti-thymocyte  globulin).  Androgens  are  always  included  in
hese  strategies,  and  are  given  in  both  the  active  stage  of  the
isease  and  following  remission.  We  were  unable  to  estab-
ish  an  association  between  androgen  administration  and
esponse  to  immunosuppressive  therapy.  The  only  difference
e  observed  was  related  to  response  time,  which  was  found
o  be  much  faster  in  patients  with  moderate  vs.  severe  dis-
ase.  Unfortunately,  due  to  the  lack  of  randomized  clinical
rials,  androgens  are  now  largely  ignored,  as  the  ﬁndings
f  existing  studies  have  shown  that  they  are  most  useful  in
atients  with  blood  disorders  (18).  In  contrast  to  the  clinical
vidence,  however,  signiﬁcant  advances  have  been  made  in
he  past  10  years.  The  lack  of  clinical  evidence  led  to  andro-
ens  being  largely  side-lined,  particularly  in  recent  years.
owever,  new  research  in  the  early  2010s  identiﬁed  a new
echanism  of  action  that  explained  the  activity  of  andro-
ens  in  marrow  failure  syndromes.  Young  et  al.  identiﬁed
he  role  played  by  telomere  shortening  in  bone  marrow  fail-
re  syndromes17.  The  function  of  these  structures  located
t  the  end  of  linear  chromosomes  is  to  protect  the  chromo-
ome  and  prevent  loss  of  genetic  material.  However,  when
hey  are  shortened,  the  cells  can  become  prone  to  apoptosis,75  68.43
enescence,  and  in  some  cases,  malignant  transformation.18
he  best  example  of  a telomeropathy,  or  disease  caused  by
elomere  shortening,  is  dyskeratosis  congenita19, in  which
ll  telomere-binding  proteins  (TERT,  TERC,  DKC1,  NOP10,
INF2)  are  altered.20 Calado  et  al.  conﬁrmed  the  effect
f  androgens  on  telomerase  expression  in  in  vitro  studies,
nding  that  exposure  to  androgens  restored  the  telomerase
xpression  and  activity  of  cells  from  patients  with  mutations
ffecting  telomerase  activity.21 Yamaguchi  et  al.,  mean-
hile,  suggested  that  telomerase  shortening  or  mutations
ay  be  caused  by  haploinsufﬁciency.22 Other  mechanisms
ave  mainly  been  associated  with  erythropoietin-mediated
aemoglobin  synthesis.  Sex  hormones  are  known  to  affect
enal  microvasculature,  insofar  as  oestrogens  dilate  and
ndrogens  constrict  blood  vessels,  and  this  action  affects
oth  venous  and  capillary  haematocrit  levels.  These  changes
ould  explain  haemoglobin  differences  between  men  and
omen.23,24
Our  study  is  limited,  as  the  data  were  collected  from
linical  records  after  implementation  of  the  particular  ther-
peutic  strategy,  and  we  had  no  control  over  the  choice  of
mmunosuppressants.  Randomized,  preferably  case-control
linical  trials  are  needed  to  corroborate  our  ﬁndings.
In  conclusion,  although  our  ﬁndings  do  not  show  that
ndrogens  affect  response  in  patients  with  aplastic  anaemia,
ew  clinical  evidence  has  shown  the  therapeutic  poten-
ial  of  these  hormones.  Randomized  studies  are  needed
o  deﬁnitively  establish  the  efﬁcacy  of  androgens  in  both
onotherapy  and  in  combination  with  other  immunosup-
ressive  regimens.
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